NewAmsterdam Total Current Liabilities from 2010 to 2024
| NAMS Stock | 20.84 0.21 1.00% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 45.3 M | Current Value 28.5 M | Quarterly Volatility 10.4 M |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 28.4 K, Net Interest Income of 3.6 M or Interest Income of 11.8 M, as well as many indicators such as Price To Sales Ratio of 68.31, Dividend Yield of 0.0 or PTB Ratio of 3.02. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Total Current Liabilities |
Latest NewAmsterdam Pharma's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of NewAmsterdam Pharma over the last few years. Total Current Liabilities is an item on NewAmsterdam Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NewAmsterdam Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. NewAmsterdam Pharma's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
NewAmsterdam Total Current Liabilities Regression Statistics
| Arithmetic Mean | 17,335,345 | |
| Geometric Mean | 15,458,545 | |
| Coefficient Of Variation | 60.06 | |
| Mean Deviation | 7,634,152 | |
| Median | 12,808,000 | |
| Standard Deviation | 10,411,795 | |
| Sample Variance | 108.4T | |
| Range | 35.5M | |
| R-Value | 0.62 | |
| Mean Square Error | 71.4T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 1,451,128 | |
| Total Sum of Squares | 1517.7T |
NewAmsterdam Total Current Liabilities History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 45.3 M | 28.5 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.